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Background: Innervation interacts with enteric immune responses. Chronic intestinal inflammation is associated
with increased risk of colorectal cancer. We aimed to study potential extrinsic neuronal modulation of intestinal
tumor development in a mouse model.
Methods: Experiments were performed with male ApcMin/+ or wild type mice (4 weeks old, body weight
approximately 20 g). Subgroups with subdiaphragmatic vagotomy (apcV/wtV), sympathetic denervation of the
small intestine (apcS/wtS) or sham operated controls (apcC/wtC) were investigated (n = 6-14 per group). Three
months after surgical manipulation, 10 cm of terminal ileum were excised, fixed for 48 h in 4% paraformaldehyde
and all tumors were counted and their area determined in mm2 (mean ± standard error of the mean (SEM)).
Whole mounts of the muscularis of terminal ileum and duodenum (internal positive control) were also stained
for tyrosine hydroxylase to confirm successful sympathetic denervation.
Results: Tumor count in ApcMin/+ mice was 62 ± 8 (apcC), 46 ± 11 (apcV) and 54 ± 8 (apcS) which was increased
compared to wildtype controls with 4 ± 0.5 (wtC), 5 ± 0.5 (wtV) and 5 ± 0.6 (wtS; all p < 0.05). For ApcMin/+ groups,
vagotomized animals showed a trend towards decreased tumor counts compared to sham operated ApcMin/+
controls while sympathetic denervation was similar to sham ApcMin/+. Area covered by tumors in ApcMin/+ mice
was 55 ± 10 (apcC), 31 ± 8 (apcV) and 42 ± 8 (apcS) mm2, which was generally increased compared to wildtype
controls with 7 ± 0.6 (wtC), 7 ± 0.4 (wtV) and 7 ± 0.6 (wtS) mm2 (all p < 0.05). In ApcMin/+ groups, tumor area was
decreased in vagotomized animals compared to sham operated controls (p < 0.05) while sympathetically denervated
mice showed a minor trend to decreased tumor area compared to controls.
Conclusions: Extrinsic innervation of the small bowel is likely to modulate tumor development in ApcMin/+ mice.
Interrupted vagal innervation, but not sympathetic denervation, seems to inhibit tumor growth.
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The autonomic nervous system plays a key role for gut
function under physiological conditions. It helps to main-
tain homeostasis by influencing secretion, peristalsis, and
smooth muscle tone to name just a few tasks [1].
Under pathological conditions, the autonomic nervous
system takes part in defense responses to toxins or path-
ogens. This was elegantly shown by Borovikova et al.
who demonstrated that vagal stimulation has a beneficial
effect on survival during sepsis which was simulated by
exposure to systemic lipopolysaccharide endotoxin [2].
The molecular basis of this interaction between auto-
nomic nervous system and immune system is the re-
lease of acetylcholine (ACh) from peripheral vagal nerve
endings. ACh binds to nicotinic ACh receptors on mac-
rophages which subsequently reduce their tumor necrosis
factor -α (TNF-α) production and release [2]. This inter-
action was named cholinergic anti-inflammatory reflex
and seems to be relevant not only during sepsis but also
when intestinal inflammation is present during colitis [3]
or postoperative ileus [4].
Acute inflammation per se is a pathological condition
that may have detrimental consequences for the organism.
Chronic inflammation, however, may trigger other path-
ologies, such as malignant transformation of epithelial
cells during ulcerative colitis or transition from chronic
pancreatitis to pancreatic cancers [5-8]. The question
arises whether this malignant transformation occurs solely
secondary to chronic inflammation or whether modula-
tion by the autonomic nervous system may also play a
role. Considering previous observations that tumor cells
carry acetylcholine receptors, this seems to be a possible
mechanism [9].
We, therefore, hypothesized that autonomic innerv-
ation to the intestine may modulate development of
intestinal tumors. Our aim was to test this hypothesis in
an established animal model of intestinal tumor develop-
ment, the ApcMin/+ mouse [10].
Methods
Animals
Experiments were performed with male ApcMin/+ k/o
mice (4 weeks old, body weight approximately 20 g).
C57BL/6 wild type animals were also investigated for
each subgroup. Presence of the ApcMin/+ knockoutFigure 1 Experimental setup and timeline.mutation was tested by RT-PCR (reverse transcriptase
polymerase chain reaction) from a tail biopsy prior to
experiments. Animal experiments were approved by the
appropriate local committee (Regierung von Oberbayern).
In ApcMin/+ mice, small intestinal tumors develop due
to a defect in the protein product of the Adenomatous
polyposis coli (APC) gene caused by a point mutation in
this gene. In consequence, in the multiple intestinal neo-
plasia (Min) mouse the Wnt/B-catenin signaling cascade
promoting cell proliferation is overactive [11].
Surgical procedures
Separate subgroups underwent subdiaphragmatic vagot-
omy, surgical denervation at the level of the superior
mesenteric artery or sham operation (laparotomy with
surgical manipulation of the small intestine for 10 min;
each n = 6–14, Figure 1).
Operations were performed following deep anesthesia
with ketamine/xylazine (Park Davis, Berlin, Germany
100 mg/kg; Bayer, Leverkusen, 15 mg/kg intraperitone-
ally). For subdiaphragmatic vagotomy, the vagus nerve
was isolated and cut at the level of the distal esophagus
under microscopic vision (operating microscope, Wild
M3Z, Heerburg, Switzerland). Small branches to the liver
were identified and also divided. For denervation at the su-
perior mesenteric artery, this vessel was isolated under
microscopic vision from all surrounding tissue. Success of
denervation here was confirmed by whole mounts of the
muscularis of terminal ileum immediately proximal to the
ileocolic junction and duodenum (internal positive con-
trol) which were obtainded at the time of final tissue har-
vest. Samples were stained for tyrosine hydroxylase
(Merck Millipore, Merck Chemicals, Schwalbach) which is
only expressed in sympathetic nerves within the enteric
plexus. It is well established that vagal fibers course within
the duodenal wall far into the distal small intestine. Surgi-
cal denervation at the level of the superior mesenteric
artery, therefore, leads to complete sympathetic denerv-
ation of the small intestine, while parts of the vagal innerv-
ation along the intestinal wall remain intact. Successful
sympathetic denervation of the small bowel was present
when lack of immunohistochemical fluorescence for tyro-
sin hydroxylase in the ileum was observed, while it was
still seen in tissue from the distal duodenum, which served
as internal positive control.
Figure 2 Representative images following denervation at the level of the superior mesenteric artery (SMA). A: Distal duodenum (internal positive
control). B: Ileum following denervation at the SMA .This figure shows a representative whole mount preparation of terminal ileum from an
animal that had undergone denervation at the level of the superior mesenteric artery (SMA). Stainings were performed for tyrosine hydroxylase
which is present on sympathetic nerve fibers. Note the absence of tyrosine hydroxylase positive fibers in ileum of denervated animals showing
lack of sympathetic innervation (B) compared to the normal distribution of sympathetic fibers in the distal duodenum which served as internal
positive control (A).
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Three months after surgery, animals were sacrificed and a
segment of 10 cm of terminal ileum beginning 1 cm prox-
imal to the ileo-colic junction was excised in all sub-
groups. The segment was cut along the mesenteric border
to expose the mucosa for evaluation of tumor numbers
and area. Then it was fixed for 48 h in 4%-paraformal-
dehyde and the tumor number and area were evaluated
(Figure 2). The distal duodenum was also harvested for
staining with tyrosine hydroxylase (Merck Millipore,
Merck Chemicals, Schwalbach) as a positive internal
control in animals that had undergone denervation at
the level of the superior mesenteric artery (Figure 3).
Data analysis
All adenomas in the 10 cm segment of terminal ileum
were counted manually with the help of a stereomicro-
scope (Olympus SZX7, Olympus GmbH, Hamburg,
Germany). The area covered by adenomas along the
10 cm segment was determined by analysis of digital
photographs taken under microscopic vision with theFigure 3 Representative images of adenoma growth in the small intestine
Representative images of adenomas in wild type (A) and ApcMin/+ animals
between both genotypes.help of dedicated software. Descriptive statistics include
mean ± SEM. Comparisons between the six subgroups
were performed using ANOVA (one way analysis of
variance). Post-hoc tests concerning comparisons be-
tween subgroups were performed using the Dunnetts
test. P-values < 0.05 were considered statistically signifi-
cant. The statistical analysis was performed with SPSS 22.
Results
A dramatic increase of tumor growth was observed in the
terminal ileum of ApcMin/+ mice compared to wildtype
control animals (Figure 4). In sham operated ApcMin/+
animals 62 ± 8 tumors were counted in the evaluated
10 cm segment of terminal ileum which was increased
compared to 4 ± 0.5 tumors in wildtype controls (p < 0.05;
Figure 4). Following subdiaphragmatic vagotomy, tumor
count was reduced to 46 ± 11 in APCmin/+ mice while
tumor count following denervation at the level of the
superior mesenteric artery was 54 ± 8 which was not sig-
nificantly different compared to sham operated ApcMin/+
animals. Tumor counts were 5 ± 0.6 in wildtype controls. A: Single polyp in C57BL/6 (wt)-mice, B: Adenomas in ApcMin/+ mice.
(B). Note the obvious difference in count and area of adenomas
Figure 4 Ileal tumor count. Number of tumors in a 10 cm segment of terminal ileum in ApcMin/+ mice and wt animals after sham operation,
vagotomy and complete mesenteric (sympathetic) denervation. Data are mean ± SEM. P < 0.05 for ApcMin/+ vs. wt (*).
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ing denervation at the mesenteric artery.
The area covered by tumors in the 10 cm segment of
terminal ileum in wildtype controls was 7 ± 0.6 mm2 fol-
lowing sham operation, 7 ± 0.4 mm2 after subdiaphrag-
matic vagotomy, and 7 ± 0.6 mm2 in animals having
undergone denervation at the level of the superior mes-
enteric artery (Figure 5). The tumor area was increased
in ApcMin/+ mice compared to corresponding wild type
animals (all p < 0.05). In ApcMin/+ mice, corresponding
areas covered by tumors were 54 ± 11 mm2 following
sham operation, 30 ± 8 mm2 after subdiaphragmatic
vagotomy, and 42 ± 8 mm2 following denervation at the
superior mesenteric artery. In ApcMin/+ groups, tumor
area was decreased in vagotomized animals compared to
sham controls (p < 0.05), while mice denervated at theFigure 5 Area covered by tumor in the terminal ileum. Tumor area was de
wt animals after sham operation, vagotomy and complete mesenteric den
APC sham vs. APC vagotomy (§).superior mesenteric artery were not different but showed
a minor trend to decreased tumor area compared to
sham operated controls.
Discussion
In the present study, we observed a decrease in adenoma
growth in ApcMin/+ animals that underwent previous
subdiaphragmatic vagotomy compared to sham operated
controls. Dissection of autonomic nerve fibers at the
level of the superior mesenteric artery, which eliminates
the sympathetic innervation to the small intestine and
leaves the vagal innervation along the intestinal wall intact,
had only a minor effect on reduction of adenoma growth.
This is the first time that a reduction of tumor growth
following vagal denervation is described in an in vivo
model of intestinal cancer. Interestingly, this effect wastermined in a 10 cm segment of terminal ileum in ApcMin/+ mice and
ervation. Data are mean ± SEM. P < 0.05 for ApcMin/+ vs. wt (*) and for
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sympathetic denervation at the level of the origin of the
superior mesenteric artery.
Complete vagal denervation of the small intestine was
ensured by cutting the ventral and dorsal trunk at the
level of the diaphragm in addition to hepatic branches.
This was done since the vagus nerve enters the abdomen
as a ventral and dorsal trunk on the esophagus. The
ventral trunk then divides into hepatic, ventral gastric
and accessory celiac branches and the dorsal trunk in
celiac and dorsal gastric branches [12]. Their branches
descend on the celiac artery to near the celiac ganglion
and then distribute to the small and large intestine along
the mesenteric artery and its offshoots [1]. Therefore,
complete vagotomy as performed in the present study at
the level of the dorsal and ventral trunks including hep-
atic branches will eliminate vagal innervation of the
stomach, duodenum and small intestine.
Denervation at the level of the superior mesenteric
artery, in which all nervous tissue is stripped from the
mesenteric artery, will destroy celiac vagal branches
which deliver the majority of vagal efferents to the small
intestine. This denervation, however, will leave the
hepatic vagal branch intact, which was shown to also
contribute to vagal innervation of the small intestine
with fibers running within the intestinal wall [13].
Denervation at the level of the superior mesenteric
artery, therefore, would leave part of the vagal innerv-
ation to the small intestine intact. This explains why a
similar decrease in tumor numbers and area was not
observed after mesenteric denervation at the superior
mesenteric artery compared to subdiaphragmatic vagot-
omy. However, sympathetic denervation of the small
intestine was complete following surgical denervation at
the superior mesenteric artery as stainings for tyrosine
hydroxylase were negative in these animals compared to
internal positive controls. Thus, the sympathetic innerv-
ation appears to have no infuence on tumor growth in
this model.
The main neurotransmitter of the efferent vagus nerve
endings is acetylcholine. ACh has been characterized as
an ubiquitous signaling molecule in neuronal as well as
non-neuronal tissues with significant influence on tumor
development. ACh activates nicotinic ligand gated ion
channel receptors as well as G-protein coupled muscar-
inic receptors [14]. Several mechanisms through which
ACh influences carcinogenesis and tumor progression
were identified so far and may underlie our observations.
This includes immunomodulatory function of ACh and
its potential role in chronic inflammation and thus can-
cer development, where ACh might promote tumor
growth through its anti-inflammatory and immunosup-
pressive actions [15,16]. ACh also has a proliferative
effect on cancer cells [17] and may play a role as animportant regulator in colorectal cancer. Signaling via
the muscarinic receptor M3 (M3R), which is overex-
pressed in colon cancer, was found to have tumor pro-
moting effects[18], as does signaling via the α7 nicotinic
acetylcholine receptor (nAChR)[19].
The cholinergic anti-inflammatory pathway is a coun-
ter–regulatory pathway of the autonomic nervous sys-
tem that contains pro- inflammatory responses. The
vagus nerve has been identified as the main conduit and
bilateral subdiaphragmatic truncal vagotomy can sup-
press this effect [20]. ACh can modulate macrophage
function via the α7 subunit of the nicotinic acetylcholine
receptor [21], thereby inhibiting the synthesis and re-
lease of the pro-inflammatory cytokines TNFα, interleu-
kin −1 (IL-1), interleukin −18 (IL-18) and interleukin-6
(IL-6) [22]. On a molecular level, activation of the α7
subunit of the nicotinic acetylcholine receptor leads to
inhibition of nuclear factor kappa B (NFκB), which is a
well-studied downstream component of the mitogen
activated protein kinases (MAPK) and regulates cell pro-
liferation as well as synthesis of pro-inflammatory cyto-
kines [3]. NFκB is prevented from translocating into the
nucleus, either through inhibiting phosphorylation of
the inhibitory protein IκBα or by activating the Jak
(januskinase) 2-STAT (Signal Transducers and Activa-
tors of Transcription) 3 anti-inflammatory signaling
pathway [23]. Following vagotomy the attenuating vagal
effect is absent with subsequently increased cytokine
levels and activation of the immune system [24]. This
increased activation is likely to enhance immune surveil-
lance with the potential consequence of decreased tumor
growth that would explain reduced tumor count and
surface area following vagotomy in our study.
Alternatively, ACh may have stimulated muscarinic
receptors. Effects on muscarinic receptors include
stimulation of carcinogenesis of colon carcinoma both
in vitro and in vivo. Muscarinic receptors are expressed
ubiquitously throughout the body and are involved in
numerous physiologic processes. They are members of
the large family of G-protein coupled receptors (GPCR).
Five receptor subtypes M1-5 have been identified [18].
The receptors primarily expressed in colon cancer are
the Gq-coupled M3 receptors (M3R). Overexpression of
M3R has been found both in human colon cancer speci-
mens [25] as well as in several colon cancer cell lines
[9]. In addition to neuronal sources from autonomic
nerve fibers, ACh is produced nonneuronally in colon
cancer cells themselves [26]. The proliferative action of
M3R depends in part on the transactivation of epidermal
growth factor receptors (EGFR), resulting in intracellular
signaling via both the MEK/ERK (mitogen-activated pro-
tein kinase kinase/extracellular signal regulated kinase)
and PI3K/AKT (phosphoinositid-3-kinase/AKT) signal-
ing pathways [27,28]. In the classical Gq pathway,
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naling events, the activation of proteinkinase C (PKC)
and the release of calcium from intracellular stores. The
transient mobilization of intracellular Ca2+ is followed
by a sustained Ca2+ influx from the extracellular space.
Both pathways converge on extracellular signal-regulated
kinases 1 and 2 (ERK1/2) activation [14]. ERK1/2 belongs
to the group of mitogen-activated protein kinases, which
are involved in various cellular functions, such as cell
growth, proliferation, differentiation and apoptosis [29].
The combined effects of EGFR and PKC inhibition are
additive, suggesting that the EGFR and PKC pathways act
in parallel to link M3R stimulation to ERK1/2 activation
[30]. In addition to this, it has been demonstrated that
M3R agonists stimulate actin stress fiber formation and
human colon cancer cell migration and invasion [31]. In
vivo, Raufman et al. showed that M3R knockout mice
were resistant to the development of colon tumors in
the azoxymethane-induced colon neoplasia model,
which confirmed the actual role of M3R in colon cancer
[32]. In the APCmin/+ mouse model, reducing M3R ex-
pression and activation attenuates intestinal epithelial
cell proliferation and neoplasia [33]. Furthermore,
tumorigenesis was shown to be inhibited via a M3R
mechanism following vagotomy in a gastric cancer
model [34]. This suggests for our study, that vagotomy
with subsequently decreased ACh release may have
inhibited M3R activation with ensuing decreased tumor
growth in these animals.
Another possible target is the α7 subunit of the nico-
tinic acetylcholine receptor, which is also expressed in
human colorectal carcinoma specimen [16] and cancer
cell lines [35]. It was demonstrated that nicotine acting
on the α7 nACHR has many tumor promoting functions
[36]. ACh could influence tumor progression in a similar
way. Activation of α7 nAChR through nicotine involves
the transactivation of EGFR through intracellular and L-
type voltage sensitive calcium channels as well as the
activation of protein kinase C (PKC). This leads to
downstream activation of the serine/threonine kinase
raf-1, the mitogen-activated kinases ERK1 and ERK2 and
the transcription factors FOS, JUN and MYC [19,36].
Nicotine has also been found to upregulate vascular
endothelial growth factor receptor (VEGFR) [19] and to
stimulate angiogenesis via the α7 nAChR [37].
Although several mechanism through which acetyl-
choline influences tumor growth have been described,
the role of the vagus nerve and the autonomic nervous
system might still be far more complex. Sympathetic
denervation did not lead to a significant reduction in
tumor growth in ApcMin/+ mice, so the mechanism
seems to be confined to the vagus nerve, potentially to
ACh. It was shown that colon cancer cells also have re-
ceptors for other neurotransmitters, such as dopamineand norepinephrine [15]. Little is known yet about the
interactions between different neurotransmitters and cy-
tokines in the development of colon tumors. The precise
molecular mechanisms by which the autonomic nervous
system modulates intestinal tumor growth, therefore,
remain to be elucidated.
In conclusion, intact vagal innervation seems to sup-
port tumor development under the special condition
of the ApcMin/+ mouse model and tumor growth was
attenuated following chronic vagotomy. The mechanism
underlying this observation remains to be explored.
Contrary to the vagus nerve, sympathetic innervation of
the small intestine appears to have no obvious influence
on tumor development.
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